Published in JAMA Intern Med on May 27, 2013
Statin medications are associated with a lower probability of having an abnormal screening prostate-specific antigen result. Urology (2014) 2.09
Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold. Urology (2014) 1.43
Reducing PSA-Based Prostate Cancer Screening in Men Aged 75 Years and Older with the Use of Highly Specific Computerized Clinical Decision Support. J Gen Intern Med (2015) 1.17
Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly. Am J Prev Med (2016) 0.76
Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study. BMC Health Serv Res (2016) 0.75
Elevated hardness of peripheral gland on real-time elastography is an independent marker for high-risk prostate cancers. Radiol Med (2017) 0.75
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol (1992) 60.45
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2012) 15.83
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Rethinking screening for breast cancer and prostate cancer. JAMA (2009) 7.83
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med (2008) 6.02
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol (2010) 6.01
PSA screening among elderly men with limited life expectancies. JAMA (2006) 5.70
Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med (1996) 5.68
Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol (2011) 5.28
Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ (2012) 4.64
Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr (2006) 4.04
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med (2008) 3.73
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst (2007) 3.07
Veterans' access to and use of Medicare and Veterans Affairs health care. Med Care (2007) 2.78
Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin (2011) 2.76
Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol (2012) 2.62
Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer (2010) 2.61
Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol (2011) 2.51
Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med (2011) 2.34
Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst (2005) 2.15
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer (2010) 2.15
Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare. J Am Geriatr Soc (2010) 2.08
Measuring complications of cancer treatment using the SEER-Medicare data. Med Care (2002) 2.05
Ability of Medicare claims data and cancer registries to identify cancer cases and treatment. Am J Epidemiol (1997) 1.58
What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med (2012) 1.54
Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both? J Urol (2005) 1.46
2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA (2012) 1.41
Prostate cancer screening--the evidence, the recommendations, and the clinical implications. JAMA (2011) 1.37
Grading the new US Preventive Services Task Force prostate cancer screening recommendation. JAMA (2011) 1.35
Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol (1999) 1.27
Missing the mark on prostate-specific antigen screening. JAMA (2011) 1.12
The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci (2012) 1.01
Primary care providers' perspectives on discontinuing prostate cancer screening. Cancer (2012) 0.92
Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer. Eur J Cancer (2010) 0.87
Comparison of 12-core versus 8-core prostate biopsy: multivariate analysis of large series of US veterans. Urology (2011) 0.79
Biopsy follow-up of prostate-specific antigen tests. Am J Prev Med (2012) 0.77
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Autonomic nerve development contributes to prostate cancer progression. Science (2013) 6.11
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst (2004) 5.84
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA (2008) 4.19
Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis (2007) 3.93
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Campylobacters as zoonotic pathogens: a food production perspective. Int J Food Microbiol (2007) 3.51
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA (2012) 3.07
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol (2005) 2.72
Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst (2002) 2.54
The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst (2008) 2.46
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology (2010) 2.45
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev (2006) 2.28
Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol (2009) 2.23
Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. Urology (2009) 2.23
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol (2008) 2.16
Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis (2008) 2.09
Association between exercise and primary incidence of prostate cancer: does race matter? Cancer (2013) 2.07
Anaerobic oxidation of methane coupled to nitrate reduction in a novel archaeal lineage. Nature (2013) 2.07
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
Levels and variation in overuse of fecal occult blood testing in the Veterans Health Administration. J Gen Intern Med (2012) 2.06
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05
Obesity and prostate cancer: weighing the evidence. Eur Urol (2012) 2.01
Prediction of recovery, dependence or death in elders who become disabled during hospitalization. J Gen Intern Med (2012) 1.99
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol (2009) 1.97
Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer (2007) 1.96
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol (2010) 1.94
The role of genetic markers in the management of prostate cancer. Eur Urol (2012) 1.88
The correlation between metabolic syndrome and prostatic diseases. Eur Urol (2011) 1.83
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol (2010) 1.82
Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol (2012) 1.81
Patterns of multimorbidity in elderly veterans. J Am Geriatr Soc (2012) 1.79
Biosynthesis and genetic regulation of proanthocyanidins in plants. Molecules (2008) 1.79
Long-term outcomes following positive fecal occult blood test results in older adults: benefits and burdens. Arch Intern Med (2011) 1.77
Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate (2012) 1.76
Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol (2009) 1.75
Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis (2008) 1.75
Validation of self-reported colorectal cancer screening behavior from a mixed-mode survey of veterans. Cancer Epidemiol Biomarkers Prev (2008) 1.72
Climate variability and campylobacter infection: an international study. Int J Biometeorol (2004) 1.69
Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer (2013) 1.66
Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol (2011) 1.66
The relationship between nutrition and prostate cancer: is more always better? Eur Urol (2012) 1.66
The influence of patient race and social vulnerability on urologist treatment recommendations in localized prostate carcinoma. Med Care (2006) 1.65
Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol (2012) 1.64
Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev (2012) 1.63
Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol (2007) 1.63
Timing of curative treatment for prostate cancer: a systematic review. Eur Urol (2013) 1.63
Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. Urology (2012) 1.62
GliZ, a transcriptional regulator of gliotoxin biosynthesis, contributes to Aspergillus fumigatus virulence. Infect Immun (2006) 1.61
Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer (2010) 1.59
Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst (2011) 1.58
Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int (2014) 1.58
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int (2011) 1.54
Use of opioids and other analgesics by older adults in the United States, 1999-2010. Pain Med (2014) 1.52
The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. Cancer (2014) 1.51
The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy. World J Urol (2012) 1.51
Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis (2007) 1.51
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res (2006) 1.50
A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol (2013) 1.48
Quality of life, pain and return to normal activities following laparoscopic donor nephrectomy versus open mini-incision donor nephrectomy. J Urol (2003) 1.47
Coreactivation of Human Herpesvirus 6 and Cytomegalovirus Is Associated With Worse Clinical Outcome in Critically Ill Adults. Crit Care Med (2015) 1.45
The effect of dietary sodium and fructose intake on urine and serum parameters of stone formation in a pediatric mouse model: a pilot study. J Urol (2013) 1.44
Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy. Urology (2012) 1.43
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Food frequency questionnaire results correlate with metabolic control in insulin-treated veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study. J Am Diet Assoc (2004) 1.42
Obesity and prostate cancer: importance of race and stage of disease. J Urol (2007) 1.41
Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy. Int J Urol (2012) 1.40
Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One (2011) 1.39
Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database. Urology (2012) 1.39
Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2009) 1.38
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36
Knowledge, attitudes and practices (KAP) relating to avian influenza in urban and rural areas of China. BMC Infect Dis (2010) 1.36
Rising PSA in nonmetastatic prostate cancer. Oncology (Williston Park) (2007) 1.35
Changing concepts in the management of renal oncocytoma. Urology (2002) 1.31
Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol (2002) 1.31
Contributions of weekly mean blood glucose values to hemoglobin A1c in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Am J Med Sci (2004) 1.30
Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol (2004) 1.30
Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control (2010) 1.29
Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. J Urol (2009) 1.28
Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol (2010) 1.28
Developing and sustaining quality improvement partnerships in the VA: the Colorectal Cancer Care Collaborative. J Gen Intern Med (2010) 1.25
A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutr Res (2011) 1.24